Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows:
— Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
— Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
— To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.
About NovavaxNovavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combinationand stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.comand LinkedInfor more information.
Contacts:
InvestorsLuis Sanay, CFA240-268-2022ir@novavax.com
MediaGiovanna Chandler202-709-5563media@novavax.com
https://mma.prnewswire.com/media/2343668/Novavax_High_Res_Logo.jpg
https://c212.net/c/img/favicon.png?sn=PH23403&sd=2025-02-20
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2024-financial-results-and-operational-highlights-on-february-27-2025-302381190.html
SOURCE Novavax, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=PH23403&Transmission_Id=202502200800PR_NEWS_USPR_____PH23403&DateId=20250220